Workflow
康惠制药: 北京市金杜律师事务所上海分所关于陕西康惠制药股份有限公司2025年第二次临时股东大会之法律意见书

Core Viewpoint - The legal opinion letter from Beijing Jindu Law Firm Shanghai Branch confirms that the second extraordinary general meeting of shareholders of Shaanxi Kanghui Pharmaceutical Co., Ltd. scheduled for September 4, 2025, complies with relevant laws and regulations [1][4]. Group 1: Meeting Procedures - The meeting is scheduled for September 4, 2025, and the notice has been published in multiple financial newspapers and the Shanghai Stock Exchange website [5]. - The meeting will be held at the company's conference room, presided over by Chairman Wang Yanling, with specific voting times outlined for both in-person and online participation [5][6]. - The legal opinion confirms that the procedures for convening and holding the meeting are in accordance with applicable laws, regulations, and the company's articles of association [5][7]. Group 2: Attendance and Voting - A total of 104 participants attended the meeting, representing 44,758,537 shares, which is 44.8123% of the total voting shares [6][7]. - The online voting system recorded participation from 98 shareholders, representing 1,342,300 shares, or 1.3439% of the total voting shares [6]. - The qualifications of the attendees and the convenor of the meeting were verified and found to be compliant with legal requirements [7]. Group 3: Voting Results - The meeting passed several resolutions with significant support, including votes of 44,588,937 shares (97.2346%) for one of the resolutions, indicating strong shareholder approval [8][10]. - The voting results for the election of directors showed overwhelming support, with votes ranging from 43,467,995 to 43,599,792 shares, all exceeding 97% approval [10][11][12]. - The legal opinion concludes that the voting procedures and results are valid and comply with relevant laws and regulations [13].